Editorial Open Access
Beyond the Single Gene: Rethinking Diagnosis in Rare Pediatric Disorders Through Integrative Genomics
María Paula Rengifo Mosquera1,3, Lina Johanna Moreno Giraldo2,3,4,*
- 1Pediatric Resident, Universidad Libre Seccional Cali. Cali, Colombia
- 2MD, Pediatrician. M.Sc. and Ph.D. Medical Genetics. Postgraduate in Clinical Bioinformatics and Genomics. Postgraduate Professor at the Health Faculty. Universidad Libre Seccional Cali. Cali, Colombia
- 3Pediatric Research Group (GRINPED), Cali, Colombia
- 4Neurogenetic and Metabolic Diseases Research Line, Cali, Colombia
Corresponding Author
Lina Johanna Moreno Giraldo, linajohannamoreno@yahoo.es
Received Date: November 04, 2025
Accepted Date: November 08, 2025
Mosquera MPR, Giraldo LJM. Beyond the Single Gene: Rethinking Diagnosis in Rare Pediatric Disorders Through Integrative Genomics. Arch Clin Pediatr. 2025;2(1):4-5.
Copyright: © 2025 Mosquera MPR, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Recommended Articles
Genetic Predisposition of Breast Cancer in the United Arab Emirates
This commentary refers to our published article, as highlighted in this article most common gene causing breast cancer in the population living in the United Arab Emirates is BRCA2 followed by BRCA1. This is the first publication discussing about clinical and pathological features of breast cancer in woman with a positive genetic mutation in the United Arab Emirates. The UAE has a rising population of a mixed ethnic population with predominantly Arabic background.
Commentary on “Epigenetically Altered T Cells Contribute to Lupus Flares”
The recently published manuscript entitled “Epigenetically Altered T Cells Contribute to Lupus Flares” summarizes recent advances in our understanding of how the environment alters the immune system to cause flares of systemic lupus erythematosus (SLE) in genetically predisposed people, and why it affects women approximately 9 times more often than men
Pharmacogenetic Variants in the DPYD and TYMS Genes are Clinically Significant Predictors of Fluoropyrimidine Toxicity: Are We Ready for Use in our Clinical Practice
Fluoropyrimidines have been extensively used for almost 6 decades to treat a variety of solid cancers, especially colon, gastric, anal, rectal, head & neck and breast. However, 31–34% of patients encountered grade 3–4 adverse events (AEs) with 0.5% mortality oftennecessitating dose reduction or discontinuation. A significant proportion of these AEs are likely to be the result of inter-individual genetic variation, in particularly such as dihydropyrimidine dehydrogenase (DPYD). DPYD gene encodes DPD, the rate-limiting enzyme responsible for catabolism of 5-FU and is responsible for >85% of 5-FU elimination.
The Clinicopathological and Genetic Characteristics of High-grade Gliomas with Histone H3.3 G34 Mutation in Teenagers and Young adults
Chromatin is composed of nucleosomes, with each nucleosome consisting of an octamer of two copies each of histones H3, H4, H2A, and H2B. Chromatin is critical for the control of transcription, replication, DNA repair and other aspects of genomic stability.
Improving Cancer Epigenetic Therapy; A Glimpse of NRF2
One of the mechanisms used by epigenetic therapy is the elevation of host cell-derived double stranded RNA (dsRNA) baseline levels through overexpression of genomic repetitive elements especially Alu retroelements. The dsRNAs trigger immunogenic responses since immune system cannot distinguish between endogenous and exogenous dsRNAs derived from viral infections; hence called “Viral mimicry response”. These dsRNAs are recognized by pattern recognition receptors (PRRs) such as MDA-5